Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when funding or meeting opportunities are announced please click on the link below.

Sign up for new announcements.

Please add ResearchGrants@BrightFocus.org to your institution’s white list to insure that the notification is not blocked by your organization’s SPAM filters.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research support through the BrightFocus Foundation (www.brightfocus.org). Please follow instructions on the notification emails for removal requests.

 
 
BrightFocus Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

 

Alzheimer's Disease Research
Completed Award

Dr. Gal Bitan

Gal Bitan, Ph.D.

University of California, Los Angeles
Los Angeles, CA

Title: Rational design of amyloid beta-protein aggregation and toxicity inhibitors
Non-Technical Title: Rational design of novel drugs for Alzheimer's disease

Duration: April 1, 2008 - March 31, 2010
Award Type: Pilot
Award Amount: $100,000

Summary:

In this project we will use a novel approach that combines our most current understanding of the molecular processes that lead to AD. We do that by "tailoring" sophisticated weapons that target what is believed to be the very first event along the pathway that leads to formation of the toxic molecules that rob AD patients of their memory and personality.

Details:

Alzheimer's disease (AD) is a current major public health threat, which despite tremendous research efforts, to date has no cure. To cure and prevent the disease we must invent drugs that treat the root of the problem. In this project we will use a novel approach that combines our most current understanding of the molecular processes that lead to AD. We do that by "tailoring" sophisticated weapons that target what is believed to be the very first event along the pathway that leads to formation of the toxic molecules that rob AD patients of their memory and personality. Unlike the direction used by most pharmaceutical companies - screening of large, random collections of molecules,our study is the first example of using a rational-design approach that is based on the three-dimensional structure of the toxic protein that causes AD.

Publications:

Hochdörffer K, März-Berberich J, Nagel-Steger L, Epple M, Meyer-Zaika W, Horn AH, Sticht H, Sinha S, Bitan G, Schrader T.J. Am Chem Soc. (2011) Rational Design of β-Sheet Ligands Against Aβ(42)-Induced Toxicity. 2011 Mar 30;133(12):4348-4358. Epub 2011 Mar 7. PubMed Icon Google Scholar Icon

Sharmistha Sinha, Dahabada H. J. Lopes, and Gal Bitan. A Key Role for Lysine Residues in Amyloid #- Protein Folding, Assembly, and Toxicity ACS Chem. Neurosci., [PMID: nd]

Sharmistha Sinha,õ Zhenming Du,a Panchanan Maiti,õ Frank-Gerrit Kla.rner,Û Thomas Schrader,Û Chunyu Wang,a and Gal Bitan*. Comparison of Three Amyloid Assembly Inhibitors: The Sugar scyllo- Inositol, the Polyphenol Epigallocatechin Gallate, and the Molecular Tweezer CLR01 [PMID:nd]

Sinha S, Lopes DH, Du Z, Pang ES, Shanmugam A, Lomakin A, Talbiersky P, Tennstaedt A, McDaniel K, Bakshi R, Kuo PY, Ehrmann M, Benedek GB, Loo JA, Klärner FG, Schrader T, Wang C, Bitan G.J. Lysine-specific molecular tweezers are broad-spectrum inhibitors of assembly and toxicity of amyloid proteins. Am Chem Soc. 2011 Oct 26;133(42):16958-69. Epub 2011 Sep 29. PubMed Icon Google Scholar Icon